ShieldPack SHIELD PACK
With you since 2022

Where would you like to start?

Services, updates, and ways to contact us, all in one place

Pricing and orders →

Use the bot or chat with us—whichever you prefer

ShieldPack posts

In reversal, American Cancer Society urges routine prostate cancer screening

About 2 min read

**American Cancer Society Reverses Stance on Prostate Cancer Screening, Recommends Routine Testing**
In a significant shift in its guidelines, the American Cancer Society (ACS) has updated its recommendations for prostate cancer screening, urging men to undergo routine testing with a prostate-specific antigen (PSA) test. The new guidelines, released on Thursday, advise men at average risk to get screened every two years from the age of 50 to 69.
This change marks a departure from the ACS's previous stance, which, in 2010, did not make universal recommendations for routine screening. Instead, men at age 50 were advised to use shared-decision making with their doctors to determine whether or not to get tested. The new guidelines are based on new evidence that shows screening can save lives and reduce the risk of overdiagnosis and overtreatment.
According to the ACS, men at average risk should get a PSA test every two years from age 50 to 69. However, men considered high-risk due to their race or family history should start testing earlier, at 45. Specifically, yearly testing starting at age 45 is recommended for all Black men, who have higher rates of prostate cancer. Non-Black men should also get yearly testing starting at 45 if a close relative was diagnosed with prostate cancer before age 65, or if more than one of their relatives has had prostate cancer.
In reversal, American Cancer Society urges routine prostate cancer screening
Men aged 70 to 74 should consult their doctor on continuing screening, while those 75 and up are not recommended to get screened. The ACS notes that advances in case management can help avoid the concerning harms from overdiagnosis and overtreatment, which can lead to erectile dysfunction and urinary incontinence.
The ACS emphasizes the importance of informed decision-making, advising all men to be aware of the risks and benefits of PSA testing. If a PSA test comes back high, the ACS recommends repeating the test before taking any next steps. If repeat testing is still high, men should get either a prostate MRI or a validated biomarker test to assess risk. Only if there is a high suspicion of cancer should men jump to a prostate biopsy.
For men diagnosed with prostate cancer, active surveillance should be the initial management strategy for those whose cancer appears to be at low risk of growing or spreading. According to the ACS, prostate cancer is one of the most common cancers in men and the second leading cause of cancer death in US men. In 2026, it is estimated that nearly 334,000 men will be diagnosed with prostate cancer, and over 36,320 will die from the disease.
The ACS's new guidelines are based on evidence that shows screening can save lives. Dr. Shanthi Sivendran, interim chief patient officer for the ACS, stated, "By catching aggressive cancers with a simple PSA blood test, you open the door to highly effective treatments that protect your future. Meanwhile, lower-risk findings can be safely managed through careful, active surveillance."

Source: Ars Technica · Technology

ShieldPack media